- Conditions
- Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
- Interventions
- Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 619 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Pain
- Interventions
- Cebranopadol, Oxycodone IR, Placebo Only, Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Sheffield, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more
- Conditions
- Prolonged QTc Interval, Pharmacokinetic
- Interventions
- 100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Human Abuse Potential
- Interventions
- Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Acute Pain
- Interventions
- Cebranopadol 400 ug, Cebranopadol 200 ug, Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Miami, Florida • Bellaire, Texas + 1 more
- Conditions
- Abuse, Drug
- Interventions
- Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
- Interventions
- Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 699 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
- Conditions
- Pharmacokinetic
- Interventions
- Cebranopadol 200 μg tablet
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida